Old 05-11-20, 06:00 PM
Seat Sniffer
Biker395's Avatar
Join Date: Sep 2007
Location: SoCal
Posts: 5,163

Bikes: 2008 Scott CR1 Pro; 2006 Schwinn Fastback Pro and 1996 Colnago Decor Super C96; 2003 Univega Alpina 700; 2000 Schwinn Super Sport

Mentioned: 17 Post(s)
Tagged: 0 Thread(s)
Quoted: 739 Post(s)
Liked 634 Times in 262 Posts
Originally Posted by genec View Post
Uh, NO.

Of course this particular network has been touted by certain folks over and over again... but this "cure" is more likely to kill.

To say that 90% of the patients treated with HCL recover successfully sounds odd to me. Isn't the recovery rate nearly that high anyway? Misleading to say the least.

I've been watching the progress of the HCL clinical trials. The results I have seen show that HCL is showing no benefit to those with more serious cases. Some have shown increased fatalities with HCL, but at least some of that that has been attributed to the fact that older and more ill patients received it. For example:

The VA study stated:

"However, hydroxychloroquine, with or without azithromycin, was more likely to be prescribed to patients with more severe disease, as assessed by baseline ventilatory status and metabolic and hematologic parameters. Thus, as expected, increased mortality was observed in patients treated with hydroxychloroquine, both with and without azithromycin. Nevertheless, the increased risk of overall mortality in the hydroxychloroquine-only group persisted after adjusting for the propensity of being treated with the drug. That there was no increased risk of ventilation in the hydroxychloroquine-only group suggests that mortality in this group might be attributable to drug effects on or dysfunction in non-respiratory vital organ systems. Indeed, hydroxychloroquine use in Covid-19 patients has been associated with cardiac toxicity."

And for another study that also showed increased fatalities when treated with HCL:

"Over a median of 22.5 days, 346 (25.1%) patients had a primary end-point event, with 180 patients being intubated (66 of whom died) and 166 patients dying without intubation. In the unadjusted analysis, patients treated with hydroxychloroquine were more than twice as likely to die or be intubated as those who didn't receive the drug (hazard ratio [HR], 2.37; 95% confidence interval [CI], 1.84 to 3.02).But when the researchers adjusted for the fact that hydroxychloroquine patients were sicker, and also accounted for factors such as age, race, body-mass index, and comorbidities, they found no significant association between treatment with hydroxychloroquine and the composite end point (HR, 1.04; 95% CI, 0.82 to 1.32). They also found no significant association between treatment with azithromycin and the composite end point (HR, 1.03; 95% CI, 0.81 to 1.31)."

That leaves the possibility that it might be effective improving endpoints or reducing treatment duration or recovery duration for patients with less severe disease. This recent publication appears to support that:


I think there are still many ongoing clinical trials on this topic. It's hard to find data on this topic without it becoming infected with politics. Is there a good source for summaries of these clinical trials/studies as they results come in?
Proud parent of a happy inner child ...

Biker395 is offline